Chiusura precedente | 0,0000 |
Aperto | 0,0000 |
Denaro | 0,0000 x N/D |
Lettera | 0,0000 x N/D |
Min-Max giorno | 0,0000 - 0,0000 |
Intervallo di 52 settimane | |
Volume | |
Media Volume | N/D |
Capitalizzazione | 32.522 |
Beta (5 anni mensile) | N/D |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,0010 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities. Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of
Basel, Switzerland, 29 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland. In total, 298’358’348 shares equalling 2
Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment